Natal’yA A. Belyaeva
Natal’yA A. Belyaeva has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Andrey A. Skorokhod
Saint Petersburg State Research Institute of Phthisiopulmonology
3 shared publications - Andrey Olegovich Nefedov
Saint Petersburg State Research Institute of Phthisiopulmonology
3 shared publications Ekaterina V. Gordeeva
Moscow Multidisciplinary Center for Palliative Care
3 shared publicationsMariya G. Kolesnichenko
Medical Center “Verax-Med” LLC
3 shared publications- Nail M. Egofarov
Nutricia LLC
3 shared publications - Olga Arkadievna Obukhova
Peoples' Friendship University of Russia
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 110-122
Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in BRAF metastatic melanoma: updated 4-year OS analyses
Introduction . Combined immune-targeted therapy is a new registered approach for treating metastatic melanoma. Identifying subgroups of patients who may benefit more from simultaneous rather than sequential administration of triple combination drugs is of current scientific interest to the medical community. Aim . To present a 4-year updated analysis of the efficacy and safety of triple therapy with atezolizumab + vemurafenib + cobimetinib (AVC) in patients with BRAF-mutated advanced melanoma in real-world clinical practice in Russia. Materials and methods . A prospective non-interventional study included 59 patients with metastatic BRAF+ melanoma receiving the triple combination of vemurafenib, cobimetinib, atezolizumab. The primary endpoint was 24-month OS. Additionally, PFS, ORR, and risk factors influencing OS were evaluated. This paper is a 4-year update of a previously published analysis. Results . The median OS in the entire population was 23.67 months (95% CI 13.19–NR), and the median PFS in the entire population was 14.97 months (95% CI 8.00–24.39). An objective response was recorded in 57.6% of patients. Cox multivariate analysis revealed a significant impact of age, presence of lung metastases, and large tumor mass (10–15 cm vs ≤6 cm) on OS. The presence of liver metastases reduced median survival by more than 2.5 times, but no significant effect was proven. BMI, ECOG ≥ 2, CNS metastases, line of therapy, and PD-L1 did not have a statistically significant effect. Conclusion . Triple therapy demonstrates high clinical efficacy in patients with metastatic BRAF+ melanoma in real-world clinical practice in the analyzed population of patients with an unfavorable prognosis – CNS involvement, liver involvement, and second-line and subsequent therapy. Age, the presence of lung metastases, and tumor size were found to be prognostic factors affecting survival.
- 1 January 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 21,p. 110-122
Open AccessTriple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in BRAF metastatic melanoma: updated 4-year OS analyses
Introduction . Combined immune-targeted therapy is a new registered approach for treating metastatic melanoma. Identifying subgroups of patients who may benefit more from simultaneous rather than sequential administration of triple combination drugs is of current scientific interest to the medical community. Aim . To present a 4-year updated analysis of the efficacy and safety of triple therapy with atezolizumab + vemurafenib + cobimetinib (AVC) in patients with BRAF-mutated advanced melanoma in real-world clinical practice in Russia. Materials and methods . A prospective non-interventional study included 59 patients with metastatic BRAF+ melanoma receiving the triple combination of vemurafenib, cobimetinib, atezolizumab. The primary endpoint was 24-month OS. Additionally, PFS, ORR, and risk factors influencing OS were evaluated. This paper is a 4-year update of a previously published analysis. Results . The median OS in the entire population was 23.67 months (95% CI 13.19–NR), and the median PFS in the entire population was 14.97 months (95% CI 8.00–24.39). An objective response was recorded in 57.6% of patients. Cox multivariate analysis revealed a significant impact of age, presence of lung metastases, and large tumor mass (10–15 cm vs ≤6 cm) on OS. The presence of liver metastases reduced median survival by more than 2.5 times, but no significant effect was proven. BMI, ECOG ≥ 2, CNS metastases, line of therapy, and PD-L1 did not have a statistically significant effect. Conclusion . Triple therapy demonstrates high clinical efficacy in patients with metastatic BRAF+ melanoma in real-world clinical practice in the analyzed population of patients with an unfavorable prognosis – CNS involvement, liver involvement, and second-line and subsequent therapy. Age, the presence of lung metastases, and tumor size were found to be prognostic factors affecting survival.
- Open Access
- 1 November 2023
- Published by ECO-Vector LLC in Clinical nutrition and metabolism
- Vol. 4 (4) , 211-222
Impact of perioperative high-protein nutritional support on the quality of life of patients with primary lung cancer: a Russian prospective multicenter comparative study (NUTRILUNC study)
BACKGROUND: Individuals over the age of 70 comprise over half of operable patients with stage 0–IIIA lung cancer. In the early postoperative period of this cohort, pain, fatigue, insomnia, and/or mood disturbances are the four most common symptoms, which can significantly diminish quality of life and functional status. Perioperative nutritional support in such patients, which enhances exercise tolerance, can have a positive impact on their quality of life and socialization. AIM: To assess the effect of perioperative nutritional support using high-protein oral nutrition supplements on the general health and quality of life of non-small cell lung cancer patients during the postoperative period. MATERIALS AND METHODS: Patients with primary non-small cell lung cancer (n=112, 69 males), aged 57.2±8.2, who were awaiting lung surgery and at risk of malnutrition (Nutritional Risk Screening Assessment 2002 score ≥3) were randomly assigned into two groups. Oral nutritional support (Nutridrink Compact Protein, Nutricia LLC) was administered to the study group (n=55) at a rate of 250 ml/d (36 g of protein, 612 kcal) for 14 days prior to and 14 days following the surgery, in addition to the standard diet. Control group patients (n=57) were provided a standard diet. The quality of life was assessed using the Quality of Life Questionnaire Core-30. Results are presented as mean ± standard deviation. Differences were considered significant at p ≤0.05. RESULTS: Throughout the entire observation period, the study group exhibited superior growth indicators in terms of general health status, physical, and role functioning than the control group (p 0.05). The study group patients exhibited a propensity toward improved emotional functioning, and by the end of the study, weakness and insomnia were less pronounced (p 0.05). Other indicators did not exhibit any significant variations. CONCLUSION: Нigh-protein perioperative oral nutrition supplements exert a positive impact on the quality of life of non-small cell lung cancer patients.
- 1 November 2023
- Published by ECO-Vector LLC in Clinical nutrition and metabolism
- Vol. 4 (4) , 211-222
Open AccessImpact of perioperative high-protein nutritional support on the quality of life of patients with primary lung cancer: a Russian prospective multicenter comparative study (NUTRILUNC study)
BACKGROUND: Individuals over the age of 70 comprise over half of operable patients with stage 0–IIIA lung cancer. In the early postoperative period of this cohort, pain, fatigue, insomnia, and/or mood disturbances are the four most common symptoms, which can significantly diminish quality of life and functional status. Perioperative nutritional support in such patients, which enhances exercise tolerance, can have a positive impact on their quality of life and socialization. AIM: To assess the effect of perioperative nutritional support using high-protein oral nutrition supplements on the general health and quality of life of non-small cell lung cancer patients during the postoperative period. MATERIALS AND METHODS: Patients with primary non-small cell lung cancer (n=112, 69 males), aged 57.2±8.2, who were awaiting lung surgery and at risk of malnutrition (Nutritional Risk Screening Assessment 2002 score ≥3) were randomly assigned into two groups. Oral nutritional support (Nutridrink Compact Protein, Nutricia LLC) was administered to the study group (n=55) at a rate of 250 ml/d (36 g of protein, 612 kcal) for 14 days prior to and 14 days following the surgery, in addition to the standard diet. Control group patients (n=57) were provided a standard diet. The quality of life was assessed using the Quality of Life Questionnaire Core-30. Results are presented as mean ± standard deviation. Differences were considered significant at p ≤0.05. RESULTS: Throughout the entire observation period, the study group exhibited superior growth indicators in terms of general health status, physical, and role functioning than the control group (p 0.05). The study group patients exhibited a propensity toward improved emotional functioning, and by the end of the study, weakness and insomnia were less pronounced (p 0.05). Other indicators did not exhibit any significant variations. CONCLUSION: Нigh-protein perioperative oral nutrition supplements exert a positive impact on the quality of life of non-small cell lung cancer patients.
- Open Access
- 15 July 2023
- Published by ECO-Vector LLC in Clinical nutrition and metabolism
- Vol. 4 (3) , 150-164
Impact of perioperative high-protein nutritional support on postoperative outcomes in the treatment of primary lung cancer: Russian prospective multicenter comparative study (NUTRILUNC-study)
BACKGROUND: Up to 60% of lung cancer pts experience weight loss. Prevalence of sarcopenia in patients (pts) with non-small cell lung cancer (NSCLC) is about 43% and is an independent predictor of worse overall survival. It was shown that nutritional support improves outcomes in pts with cancer. AIM: To evaluate impact of perioperative nutritional support on surgical treatment outcomes of patients with NSCLC. MATERIALS AND METHODS: Patients with primary NSCLC (n=112, 69 males), aged 57,2±8,2, awaiting lung surgery and being at risk of malnutrition (Nutritional Risk Screening Assessment 2002 score ≥3) were randomized into 2 groups. Study group (n=55) received oral nutritional support (Nutridrink Compact Protein, Nutricia LLC), 250 ml/d (36 g of protein, 612 kcal) for 14 d before and 14 d after surgery in addition to standard diet. Control group (n=57) had a standard diet. The number of respiratory complications after surgery, length of hospitalization, anthropometric, functional, laboratory parameters, quality of life (according to Quality of Life Questionnaire Core-30) were assessed. Results were presented as mean ± standard deviation. Differences were considered significant at p ≤0.05. RESULTS: In the study group there were fewer respiratory complications (p 0.01), and a shorter length of hospitalization (p=0.03). Body weight in the study group did not change significantly, while in the control group it decreased (0.15±3.7 kg versus loss of 3.47±3.6 kg). Results of six-minute walk test and hand grip dynamometry were higher in the study group then in the control group (411.8±56.0 m versus 383.2±52.1 m; 33.5±8.4 kg versus 27.1±6.8 kg). Quality of life was better in the study group, p 0.05. The total protein and albumin levels were higher in the study group (70.9±5.6 g/l versus 63.1±4.0 g/l; 38.5±5.8 g/l versus 33.2±3.0 g/l). One patient in study group experienced 1st grade diarrhea. CONCLUSION: In patients with NSCLC at risk of malnutrition perioperative nutritional support with high protein oral nutritional support has a positive effect on surgical treatment outcomes.
- 15 July 2023
- Published by ECO-Vector LLC in Clinical nutrition and metabolism
- Vol. 4 (3) , 150-164
Open AccessImpact of perioperative high-protein nutritional support on postoperative outcomes in the treatment of primary lung cancer: Russian prospective multicenter comparative study (NUTRILUNC-study)
BACKGROUND: Up to 60% of lung cancer pts experience weight loss. Prevalence of sarcopenia in patients (pts) with non-small cell lung cancer (NSCLC) is about 43% and is an independent predictor of worse overall survival. It was shown that nutritional support improves outcomes in pts with cancer. AIM: To evaluate impact of perioperative nutritional support on surgical treatment outcomes of patients with NSCLC. MATERIALS AND METHODS: Patients with primary NSCLC (n=112, 69 males), aged 57,2±8,2, awaiting lung surgery and being at risk of malnutrition (Nutritional Risk Screening Assessment 2002 score ≥3) were randomized into 2 groups. Study group (n=55) received oral nutritional support (Nutridrink Compact Protein, Nutricia LLC), 250 ml/d (36 g of protein, 612 kcal) for 14 d before and 14 d after surgery in addition to standard diet. Control group (n=57) had a standard diet. The number of respiratory complications after surgery, length of hospitalization, anthropometric, functional, laboratory parameters, quality of life (according to Quality of Life Questionnaire Core-30) were assessed. Results were presented as mean ± standard deviation. Differences were considered significant at p ≤0.05. RESULTS: In the study group there were fewer respiratory complications (p 0.01), and a shorter length of hospitalization (p=0.03). Body weight in the study group did not change significantly, while in the control group it decreased (0.15±3.7 kg versus loss of 3.47±3.6 kg). Results of six-minute walk test and hand grip dynamometry were higher in the study group then in the control group (411.8±56.0 m versus 383.2±52.1 m; 33.5±8.4 kg versus 27.1±6.8 kg). Quality of life was better in the study group, p 0.05. The total protein and albumin levels were higher in the study group (70.9±5.6 g/l versus 63.1±4.0 g/l; 38.5±5.8 g/l versus 33.2±3.0 g/l). One patient in study group experienced 1st grade diarrhea. CONCLUSION: In patients with NSCLC at risk of malnutrition perioperative nutritional support with high protein oral nutritional support has a positive effect on surgical treatment outcomes.
- Open Access
- 31 May 2023
- Published by ECO-Vector LLC in Clinical nutrition and metabolism
- Vol. 4 (1) , 5-18
The impact of perioperative high-protein oral nutrition supplements on postoperative outcomes in primary lung cancer: the protocol of Russian prospective, randomised, multicenter study
BACKGROUND: Nutritional support, including oral nutrition supplements, is an integral part of anticancer treatment, including during surgical treatment of non-small cell lung cancer. Existing evidence for the effectiveness of nutritional support in this cohort of patients is limited. We suggest that the perioperative administration of a balanced polymeric hypercaloric high-protein enteral nutritional formula by sipping as an additional nutrition can have a positive effect on the results of surgical treatment. AIMS: 1) to assess the impact of perioperative nutritional support with high-protein oral nutrition supplements on the risk of postoperative complications, postoperative recovery of respiratory functions, nutritional status and quality of life in patients with primary lung cancer; 2) identification of possible side effects and complications when using high-protein high-energy oral nutrition supplements in patients with non-small cell lung cancer. MATERIALS AND METHODS: Russian prospective, randomised, multicenter low-intervention study of perioperative effect of high-protein nutritional support on postoperative outcomes in the treatment of primary lung cancer with parallel groups, 1:1 randomization. The study will include 114 patients with primary non-small cell lung cancer who are scheduled for surgery. It is expected to provide nutritional support in the perioperative period for 14 days before surgery and for 14 days after it. CONCLUSION: The present study may become one of the first evidence-based studies confirming the effectiveness of perioperative nutritional support with high-protein mixtures in patients with non-small cell lung cancer and will allow further study of the strategy of nutritional support in this category of patients.
- 31 May 2023
- Published by ECO-Vector LLC in Clinical nutrition and metabolism
- Vol. 4 (1) , 5-18
Open AccessThe impact of perioperative high-protein oral nutrition supplements on postoperative outcomes in primary lung cancer: the protocol of Russian prospective, randomised, multicenter study
BACKGROUND: Nutritional support, including oral nutrition supplements, is an integral part of anticancer treatment, including during surgical treatment of non-small cell lung cancer. Existing evidence for the effectiveness of nutritional support in this cohort of patients is limited. We suggest that the perioperative administration of a balanced polymeric hypercaloric high-protein enteral nutritional formula by sipping as an additional nutrition can have a positive effect on the results of surgical treatment. AIMS: 1) to assess the impact of perioperative nutritional support with high-protein oral nutrition supplements on the risk of postoperative complications, postoperative recovery of respiratory functions, nutritional status and quality of life in patients with primary lung cancer; 2) identification of possible side effects and complications when using high-protein high-energy oral nutrition supplements in patients with non-small cell lung cancer. MATERIALS AND METHODS: Russian prospective, randomised, multicenter low-intervention study of perioperative effect of high-protein nutritional support on postoperative outcomes in the treatment of primary lung cancer with parallel groups, 1:1 randomization. The study will include 114 patients with primary non-small cell lung cancer who are scheduled for surgery. It is expected to provide nutritional support in the perioperative period for 14 days before surgery and for 14 days after it. CONCLUSION: The present study may become one of the first evidence-based studies confirming the effectiveness of perioperative nutritional support with high-protein mixtures in patients with non-small cell lung cancer and will allow further study of the strategy of nutritional support in this category of patients.